GlassScriptPhysician profile
Nicholas Keaton
NPI 1245617216
$697.39
in general payments reported to CMS, 2019-2025
15 companies · $60.80 in 2025
The $60.80 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.54 · 2020: $45.13 · 2021: $75.58 · 2022: $53.16 · 2023: $120 · 2024: $302 · 2025: $60.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $154.56 | 2022-2024 | Xarelto |
| Ucb, INC. | $93.82 | 2022-2023 | Briviact |
| Mallinckrodt Hospital Products INC. | $93.58 | 2024-2025 | Terlivaz |
| Lexicon Pharmaceuticals, INC. | $83.71 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $47.01 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $35.06 | 2024 | |
| Alexion Pharmaceuticals, INC. | $30.38 | 2024 | Ultomiris |
| Pfizer INC. | $29.05 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.31 | 2020 | |
| Vifor Pharma, INC. | $27.31 | 2019 | |
| Abbvie INC. | $16.82 | 2020 | |
| Boston Scientific Corporation | $15.96 | 2024 | Watchman Access System |
| Grt US Holding, INC. | $14.82 | 2021 | |
| Amgen INC. | $13.75 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.25 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Keaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.